Dr. Reddy's API Manufacturing Capabilities:
Dr. Reddy’s manufactures 250+ APIs across India, Mexico, and the UK, with eight USFDA-inspected cGMP facilities—six in India, one in Mexico, and one in the UK. All facilities comply with ICH Q7 guidelines and are regularly audited by global regulatory authorities including USFDA, EMA, ANVISA, PMDA, Health Canada, and others.
With 40+ years of technical leadership, we specialize in complex APIs such as steroids, peptides, long-chain molecules, and HPAPIs. Our R&D teams develop robust, scalable processes and support customers through dossier filings and commercialization worldwide.
Reliable, Sustainable Supply Chain
- Multi-sourced KSMs for supply resilience
- Stringent quality specifications and timely deliveries
- Capacity expansion to meet global demand for essential APIs
Dr. Reddy’s combines deep scientific expertise, global compliance, and sustainable manufacturing to be your trusted API partner.
40+ Years of Expertise
Leading supplier of APIs for more than 40 years, with an industry leading portfolio of generic APIs and partner of choice for global formulators.
8 Manufacturing units
We have 8 commercial USFDA inspected API plants/production units, of which 6 are in India and 1 in Uk and 1 in Mexico.
Manufacturing Capacity
Sufficient manufacturing capacity and flexible batch sizes enable fast turnaround times, supported by backward integration and a resilient supply chain to ensure consistent, uninterrupted delivery.
Safety and Compliance
All our plants are operated in accordance with cGMP (ICH Q7a) and are regularly inspected/audited by international authorities and agencies.
Manufacturing Locations
- Mirfield, UK
- Cuernavaca, Mexico
- CTO VI Vizag & CTO-SEZ Vizag
- CTO - I, II, III, Hyderabad
- CTO - V (Miryalaguda, Nalgonda)
We are here to help, if you have any country specific requirements.
Manufacturing Capabilities
- 250+ APIs
- 4,100+ KL of reactor volumes.
- 1250+ Reactors including ~100+ reactors with containment across 4 sites (HPAI /Oncology/ steroids/prostaglandins).
- 5,000+ MT of Intermediates manufactured.
- 90% of our API pipeline is forward integrated to generic formulations.
- 100+ Commercial Molecules
- 50+ Pipeline molecules (Filed + under development).
- 2,100+ MT of APIs manufactured.
- Deep expertise in handing complex peptide molecules.
- Can handle molecules of OEL up to 0.1 µg/m3 by protecting environment, people & product.
Quality Control
Quality Control Policies
A key component in quality control in pharmaceutical industry is helping customers by providing a quality product. We achieve this by ensuring that all our facilities operate efficiently and to the latest quality, safety, and productivity standards.
At Dr. Reddy’s, quality control is central to our commitment to delivering safe, high-quality APIs. Our facilities operate under cGMP (ICH Q7) standards, ensuring global regulatory compliance and consistent product performance.
Advanced Analytical & Process Excellence
- Scalable manufacturing for consistent quality
- Robust analytical methods to eliminate nitrosamine and azido impurities
- Comprehensive impurity profiling, characterization, and control
- Use of advanced techniques to define chemical and physical attributes
- Efficient operations aligned with the latest quality, safety, and productivity standards
Quality Assurance
The pharmaceutical quality assurance (QA) team at Dr. Reddy’s continually monitors various facets of the quality management system. We are committed to maintaining highest quality standards in cGMP manufacturing through periodic reviews and continuous improvement of quality management system. All our manufacturing units have undergone multiple cGMP audits by various regulatory authorities, and numerous quality audits by various customers. As a result, our high-quality APIs meets all the formulation needs for various global markets.
Review Meetings for Quality Control
Dr. Reddy’s maintains a robust quality system through continuous monitoring, cross-functional audits, and harmonized procedures across all API manufacturing units. Every facility operates under cGMP (ICH Q7) and is regularly inspected by global regulatory authorities.
Recognized for our strong compliance record, we support customers with:
- DMF, CMC, IND, and NDA filings
- Deep experience with USFDA, EMA, WHO GMP, PMDA, KFDA, ANVISA, Health Canada, and more
Related Pages
R & D
Customer Service
Regulatory
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.